Talphera Inc (STU:R5XA)
€ 0.831 0.011 (1.34%) Market Cap: 14.30 Mil Enterprise Value: 4.75 Mil PE Ratio: 0 PB Ratio: 1.21 GF Score: 40/100

AcelRx Pharmaceuticals, Inc. - Special Call Transcript

Oct 07, 2020 / 04:00PM GMT
Release Date Price: €25
Operator

Good afternoon, everyone, and welcome to the AcelRx Virtual KOL Event on Perioperative Use of DSUVIA. I would now like to turn the call over to Vince Angotti, CEO of AcelRx Pharmaceuticals.

Vincent J. Angotti
AcelRx Pharmaceuticals, Inc. - CEO & Director

Thank you, operator. And thanks to all of you for your attendance and interest in AcelRx today, and welcome to our KOL call with Dr. Tvetenstrand and Cassavaugh, who will be sharing their real-world experience and data on the perioperative use of DSUVIA and their perspective on this use. This very recent data has been extremely well-received at advisory boards and other institutions, and we thought it was important to share it with our investor audience as well. While most of you are aware of the DoD's history of interest in DSUVIA and its potential application in the ER setting, today's conference will provide insight into how it is considered by health care practitioners in the surgery setting.

Today's content is strictly focused on the medical aspect of DSUVIA, and out of respect for our

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot